Loading…
Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease
To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneum...
Saved in:
| Published in: | The Journal of infectious diseases 1995-08, Vol.172 (2), p.551-553 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c383t-784d8434c0f0ffb9f201fa07af8697f14b0e18a2acf994403771c3ce8f1144493 |
|---|---|
| cites | |
| container_end_page | 553 |
| container_issue | 2 |
| container_start_page | 551 |
| container_title | The Journal of infectious diseases |
| container_volume | 172 |
| creator | Vandenbruaene, Marc Colebunders, R. Mascart-Lemone, F. Haerden, Y. Van Hove, D. Peeters, M. Goeman, J. Van Royen, P. Avonts, D. |
| description | To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30–45 days later were compared. The ratios of titers after and before vaccination in patients with >500,200–500, and |
| doi_str_mv | 10.1093/infdis/172.2.551 |
| format | article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_77417410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30135807</jstor_id><sourcerecordid>30135807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-784d8434c0f0ffb9f201fa07af8697f14b0e18a2acf994403771c3ce8f1144493</originalsourceid><addsrcrecordid>eNpFkE1rGzEURUVpSd00-24KWpTuxnn6mJG0NEkam6YkpEkw3QhZIwWlM5IzmoH631fFbgIP3uLcexcHoU8E5gQUOw3RtyGfEkHndF7X5A2akZqJqmkIe4tmAJRWRCr1Hn3I-QkAOGvEEToSDaUK2Az1F8-T6fDq8RIv4hg2qd3hW5e3KWaHx4Rvopv6ZJO1JfVgrA3RjCFFHCJedB3-OZpHl3HyeDn1JuJV308xtc4HG1y0O_wQhinj85Cdye4jeudNl93J4R-j-28Xd2fL6ur6cnW2uKosk2yshOSt5Ixb8OD9RnkKxBsQxstGCU_4BhyRhhrrleIcmBDEMuukJ4Rzrtgx-rrf3Q7peXJ51H3I1nWdiS5NWQvBSTkoQdgH7ZByHpzX2yH0ZthpAvqfYb03rIthTXUxXCqfD9vTpnftS-GgtPAvB25ykeYHE20Z-B9jDSVKNq8zT3lMwysGwmoJovBqz0Me3Z8XbobfuhFM1Hq5_qVvJPuhvt-t9Zr9Bbqlng4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77417410</pqid></control><display><type>article</type><title>Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease</title><source>Oxford University Press Archive</source><creator>Vandenbruaene, Marc ; Colebunders, R. ; Mascart-Lemone, F. ; Haerden, Y. ; Van Hove, D. ; Peeters, M. ; Goeman, J. ; Van Royen, P. ; Avonts, D.</creator><creatorcontrib>Vandenbruaene, Marc ; Colebunders, R. ; Mascart-Lemone, F. ; Haerden, Y. ; Van Hove, D. ; Peeters, M. ; Goeman, J. ; Van Royen, P. ; Avonts, D.</creatorcontrib><description>To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30–45 days later were compared. The ratios of titers after and before vaccination in patients with >500,200–500, and <200 CD4 1ymphocytes/µL were 10, 10, and 12.6, respectively. Nonresponse (ratio <4) occurred in 17% of patients and was unrelated to CD4 cell count. The vaccine was well tolerated; no serious side effects occurred. In 83% of the patients with HIV infection, the total antipneumococcal IgG level was higher after vaccination.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/172.2.551</identifier><identifier>PMID: 7622903</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; AIDS ; AIDS/HIV ; Antibodies ; Antibody Formation ; Antigens ; Bacterial Vaccines - immunology ; Biological and medical sciences ; CD4 Lymphocyte Count ; Concise Communications ; Female ; HIV ; HIV infections ; HIV Infections - immunology ; HIV Seropositivity - immunology ; Humans ; Immune response ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulin G - blood ; Immunopathology ; Male ; Medical sciences ; Pneumococcal vaccine ; Pneumococcal Vaccines ; Polysaccharides ; Streptococcus pneumoniae - immunology ; Vaccination</subject><ispartof>The Journal of infectious diseases, 1995-08, Vol.172 (2), p.551-553</ispartof><rights>Copyright 1995 The University of Chicago</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-784d8434c0f0ffb9f201fa07af8697f14b0e18a2acf994403771c3ce8f1144493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3621986$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7622903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vandenbruaene, Marc</creatorcontrib><creatorcontrib>Colebunders, R.</creatorcontrib><creatorcontrib>Mascart-Lemone, F.</creatorcontrib><creatorcontrib>Haerden, Y.</creatorcontrib><creatorcontrib>Van Hove, D.</creatorcontrib><creatorcontrib>Peeters, M.</creatorcontrib><creatorcontrib>Goeman, J.</creatorcontrib><creatorcontrib>Van Royen, P.</creatorcontrib><creatorcontrib>Avonts, D.</creatorcontrib><title>Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30–45 days later were compared. The ratios of titers after and before vaccination in patients with >500,200–500, and <200 CD4 1ymphocytes/µL were 10, 10, and 12.6, respectively. Nonresponse (ratio <4) occurred in 17% of patients and was unrelated to CD4 cell count. The vaccine was well tolerated; no serious side effects occurred. In 83% of the patients with HIV infection, the total antipneumococcal IgG level was higher after vaccination.</description><subject>Adult</subject><subject>AIDS</subject><subject>AIDS/HIV</subject><subject>Antibodies</subject><subject>Antibody Formation</subject><subject>Antigens</subject><subject>Bacterial Vaccines - immunology</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Concise Communications</subject><subject>Female</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV Infections - immunology</subject><subject>HIV Seropositivity - immunology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulin G - blood</subject><subject>Immunopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pneumococcal vaccine</subject><subject>Pneumococcal Vaccines</subject><subject>Polysaccharides</subject><subject>Streptococcus pneumoniae - immunology</subject><subject>Vaccination</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNpFkE1rGzEURUVpSd00-24KWpTuxnn6mJG0NEkam6YkpEkw3QhZIwWlM5IzmoH631fFbgIP3uLcexcHoU8E5gQUOw3RtyGfEkHndF7X5A2akZqJqmkIe4tmAJRWRCr1Hn3I-QkAOGvEEToSDaUK2Az1F8-T6fDq8RIv4hg2qd3hW5e3KWaHx4Rvopv6ZJO1JfVgrA3RjCFFHCJedB3-OZpHl3HyeDn1JuJV308xtc4HG1y0O_wQhinj85Cdye4jeudNl93J4R-j-28Xd2fL6ur6cnW2uKosk2yshOSt5Ixb8OD9RnkKxBsQxstGCU_4BhyRhhrrleIcmBDEMuukJ4Rzrtgx-rrf3Q7peXJ51H3I1nWdiS5NWQvBSTkoQdgH7ZByHpzX2yH0ZthpAvqfYb03rIthTXUxXCqfD9vTpnftS-GgtPAvB25ykeYHE20Z-B9jDSVKNq8zT3lMwysGwmoJovBqz0Me3Z8XbobfuhFM1Hq5_qVvJPuhvt-t9Zr9Bbqlng4</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Vandenbruaene, Marc</creator><creator>Colebunders, R.</creator><creator>Mascart-Lemone, F.</creator><creator>Haerden, Y.</creator><creator>Van Hove, D.</creator><creator>Peeters, M.</creator><creator>Goeman, J.</creator><creator>Van Royen, P.</creator><creator>Avonts, D.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease</title><author>Vandenbruaene, Marc ; Colebunders, R. ; Mascart-Lemone, F. ; Haerden, Y. ; Van Hove, D. ; Peeters, M. ; Goeman, J. ; Van Royen, P. ; Avonts, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-784d8434c0f0ffb9f201fa07af8697f14b0e18a2acf994403771c3ce8f1144493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>AIDS/HIV</topic><topic>Antibodies</topic><topic>Antibody Formation</topic><topic>Antigens</topic><topic>Bacterial Vaccines - immunology</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Concise Communications</topic><topic>Female</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV Infections - immunology</topic><topic>HIV Seropositivity - immunology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulin G - blood</topic><topic>Immunopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pneumococcal vaccine</topic><topic>Pneumococcal Vaccines</topic><topic>Polysaccharides</topic><topic>Streptococcus pneumoniae - immunology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vandenbruaene, Marc</creatorcontrib><creatorcontrib>Colebunders, R.</creatorcontrib><creatorcontrib>Mascart-Lemone, F.</creatorcontrib><creatorcontrib>Haerden, Y.</creatorcontrib><creatorcontrib>Van Hove, D.</creatorcontrib><creatorcontrib>Peeters, M.</creatorcontrib><creatorcontrib>Goeman, J.</creatorcontrib><creatorcontrib>Van Royen, P.</creatorcontrib><creatorcontrib>Avonts, D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vandenbruaene, Marc</au><au>Colebunders, R.</au><au>Mascart-Lemone, F.</au><au>Haerden, Y.</au><au>Van Hove, D.</au><au>Peeters, M.</au><au>Goeman, J.</au><au>Van Royen, P.</au><au>Avonts, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>172</volume><issue>2</issue><spage>551</spage><epage>553</epage><pages>551-553</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30–45 days later were compared. The ratios of titers after and before vaccination in patients with >500,200–500, and <200 CD4 1ymphocytes/µL were 10, 10, and 12.6, respectively. Nonresponse (ratio <4) occurred in 17% of patients and was unrelated to CD4 cell count. The vaccine was well tolerated; no serious side effects occurred. In 83% of the patients with HIV infection, the total antipneumococcal IgG level was higher after vaccination.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>7622903</pmid><doi>10.1093/infdis/172.2.551</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1995-08, Vol.172 (2), p.551-553 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77417410 |
| source | Oxford University Press Archive |
| subjects | Adult AIDS AIDS/HIV Antibodies Antibody Formation Antigens Bacterial Vaccines - immunology Biological and medical sciences CD4 Lymphocyte Count Concise Communications Female HIV HIV infections HIV Infections - immunology HIV Seropositivity - immunology Humans Immune response Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunoglobulin G - blood Immunopathology Male Medical sciences Pneumococcal vaccine Pneumococcal Vaccines Polysaccharides Streptococcus pneumoniae - immunology Vaccination |
| title | Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of Human Immunodeficiency Virus Disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Equal%20IgG%20Antibody%20Response%20to%20Pneumococcal%20Vaccination%20in%20All%20Stages%20of%20Human%20Immunodeficiency%20Virus%20Disease&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Vandenbruaene,%20Marc&rft.date=1995-08-01&rft.volume=172&rft.issue=2&rft.spage=551&rft.epage=553&rft.pages=551-553&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/172.2.551&rft_dat=%3Cjstor_proqu%3E30135807%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c383t-784d8434c0f0ffb9f201fa07af8697f14b0e18a2acf994403771c3ce8f1144493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77417410&rft_id=info:pmid/7622903&rft_jstor_id=30135807&rfr_iscdi=true |